360, rue des Entrepreneurs
Montmagny
Québec, QC G5V 4T1
Canada
514 248 7509
https://groupedevonian.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 6
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Luc D. Gregoire CA, CPA | President, CEO & Director | N/A | N/A | 1960 |
Ms. Colette Laurin C.A., CPA | Interim CFO, Corporate Secretary & Corporate Controller | 181,61k | N/A | N/A |
Dr. Andre P. Boulet Ph.D. | Chief Scientific Officer & Director | 644,63k | N/A | 1959 |
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada.
Devonian Health Group Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.